Longeveron Inc. (LGVN)
NASDAQ: LGVN · Real-Time Price · USD
2.480
+0.110 (4.64%)
At close: Oct 9, 2026, 4:00 PM EDT
2.350
-0.130 (-5.24%)
After-hours: Oct 9, 2026, 7:04 PM EDT
Longeveron Employees
Longeveron had 38 employees as of December 31, 2025. The number of employees increased by 12 or 46.15% compared to the previous year. That makes Longeveron the 36,157th largest employer in the world and 4,965th in the United States.
Employees
38
Change (1Y)
12
Growth (1Y)
46.15%
Revenue / Employee
$31,237
Profits / Employee
-$617,737
Market Cap
7.91M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 38 | 12 | 46.15% | 38 | 0 |
| Dec 31, 2024 | 26 | 2 | 8.33% | 26 | 0 |
| Dec 31, 2023 | 24 | 3 | 14.29% | 23 | 1 |
| Dec 31, 2022 | 21 | 1 | 5.00% | 19 | 2 |
| Dec 31, 2021 | 20 | 8 | 66.67% | 18 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bolt Biotherapeutics | 23 |
| Moleculin Biotech | 17 |
| FibroBiologics | 15 |
| CalciMedica | 15 |
| Soligenix | 14 |
| Azitra | 13 |
| CNS Pharmaceuticals | 8 |
| Aprea Therapeutics | 8 |
LGVN News
- 11 days ago - Longeveron to Participate in Three Longevity/Aging Investment Conferences - GlobeNewsWire
- 24 days ago - Longeveron Stock (LGVN) Plummets 56% on a Failed Clinical Trial - TipRanks
- 25 days ago - Longeveron explores strategic options after therapy fails mid-stage trial for infant heart condition - Reuters
- 25 days ago - Longeveron down 55% at $2.98 after resumption of trade - TheFly
- 25 days ago - Longeveron Inc trading resumes - TheFly
- 25 days ago - Longeveron to resume trading at 5:55 pm ET - TheFly
- 25 days ago - Longeveron’s laromestrocel did not meet primary endpoint in Phase 2b HLHS trial - TheFly
- 25 days ago - Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) - GlobeNewsWire